Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma	Resectable Head and Neck Squamous Cell Carcinoma	Recruiting	Phase 2	2026-05-13		NCT07492914

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
West China Hospital	359

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
West China Hospital of Sichuan University	Chengdu	China	117

Clinical trials